Category: Patent Profiles

    By Donald Zuhn — Ryogen LLC recently announced that the U.S. Patent and Trademark Office had issued U.S. Patent Nos. 7,468,266 and 7,470,522.  The '266 patent is directed to an isolated genomic polynucleotide encoding human lipoprotein-associated phospholipase A2, as well as vectors and host cells comprising such polynucleotides, antisense oligonucleotides to such polynucleotides, and…

    By Sherri Oslick — Thrasos Therapeutics, a Hopkinton, MA based biotechnology company, announced earlier this week the issuance of U.S. Patent No. 7,482,329 ("Single Domain TDF-Related Compounds and Analogs Thereof," issued January 27, 2009) directed to small molecules that selectively activate the key receptors of the bone morphogenetic protein (BMP) family.  BMPs are part…

    By Donald Zuhn — Last week, Vermillion, Inc. announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for its application directed to diagnostic methods using hepcidin as a biomarker for ovarian cancer.  The patent that eventually issues from the allowed application will be the Fremont, CA-based molecular diagnostics company's…

    By Sherri Oslick — EXACT Sciences Corp. announced today the issuance of U.S. Patent No. 7,485,420, entitled "Methods and Compositions for Detecting Colon Cancers," which is directed toward the use of differentially methylated vimentin as a marker of colorectal cancer.  The patent is assigned to Case Western Reserve University, and licensed exclusively by EXACT…

    By Donald Zuhn — On Monday, Neuralstem, Inc. announced that the U.S. Patent and Trademark Office allowed U.S. Application No. 10/047,352 (U.S. Patent Publication No. 2002/0064873), entitled "Stable neural stem cell lines."  The '352 application, which was allowed on January 13th, is directed to a method for establishing stable neural stem cell lines and…

    By Donald Zuhn — Last week, Cytori Therapeutics, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 7,473,420.  The '420 patent, which is directed to a method of treating patients with stem cells obtained from adipose tissue, is Cytori's sixth U.S. patent.  The San Diego-based biotech company is also…

    By Donald Zuhn — Last month, Epitomics Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,431,927, which is directed to monoclonal antibodies that neutralize TNF-alpha activity.  The Burlingame, California-based biotech company also announced that the USPTO has issued U.S. Patent No. 7,429,487, which is directed to a rabbit-derived…

    By Donald Zuhn — Last week, Immunomedics, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,435,803, which is directed to humanized and chimeric anti-CD20 antibodies and CD20 antibody fusion proteins.  Such antibodies are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune…

    By Donald Zuhn — Earlier this month, eGenomics, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,349,808, which is directed to a method for performing real-time infection control by determining the phylogenetic relatedness between sequence data obtained from a microorganism sample isolated in a health care facility…

    By Donald Zuhn — Last week, Allele Biotechnology & Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,422,896, which is directed to DNA compositions that mediate RNA interference (RNAi) gene silencing, wherein the DNA compositions include an RNA polymerase III promoter that drives the expression of…